Lifeforce Capital

Vilya is a biotechnology company focused on developing innovative drugs that specifically target the biology of diseases. The company employs a unique platform that explores uncharted chemical space to design new molecular structures, which are intermediate in size between small molecules and antibodies. These structures possess essential drug-like properties, such as the capacity to traverse biological membranes and disrupt protein-protein interactions. By leveraging advanced computing techniques, Vilya aims to make traditional high throughput screening methods obsolete, ultimately working towards the creation of new medicines that can effectively treat a range of diseases.

Ochre Bio Ltd is a biotechnology company focused on developing genomic medicines to improve outcomes for liver transplant patients. Established in 2019 and headquartered in Headington, United Kingdom, the company specializes in rejuvenating donor livers before transplantation, ensuring that more patients in need of a new liver receive one. Utilizing advanced genomic techniques, Ochre Bio identifies and targets over-active genes that contribute to liver diseases. The company tests its novel RNA-based therapies on discarded donor livers kept alive outside the body, allowing for direct evaluation of treatment efficacy. With roots in over 15 years of liver genomics research, Ochre Bio aims to address liver-related conditions and enhance the availability of healthy livers for transplantation.

Transition Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom. Founded in 2020, the company specializes in the discovery, analysis, and modulation of biological condensates. It has developed a unique platform, known as Condensomics, which facilitates hypothesis-free drug discovery and diagnostics. Transition Bio utilizes advanced droplet microfluidic techniques and protein biophysics to characterize condensates with high precision, thereby creating extensive opportunities for drug development. The company's innovative approach aims to advance human health care by providing detailed insights into molecular structures.

MindRight Health, Inc., founded in 2019 and based in Newark, New Jersey, offers mental health coaching through text messaging to support communities in overcoming trauma. The company aims to enhance health equity by providing accessible and inclusive mental health care, particularly for communities of color and low-income families. MindRight partners with healthcare payers and providers to deliver culturally-responsive coaching, ensuring that members receive support seven days a week throughout the year. By matching users with specific coaches based on their profiles, MindRight creates a continuum of nonclinical support tailored to youth who may avoid traditional clinical services due to stigma and accessibility issues. Additionally, the company supplies partners with real-time data on mental health needs within the community, helping to anticipate and prevent potential mental health crises.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

Founded in 2021, Cylinder delivers personalized, clinician-backed care to those suffering from digestive issues through its virtual health platform and has helped nearly 100K members to date. Cylinder's platform offers dynamically updated content and care plans designed to improve engagement and outcomes. Members enjoy access to a dedicated care team nationwide, including health coaches, registered dietitians, and GI doctors. Cylinder’s vision is to create a world where people receive convenient, personalized, and affordable access to the quality digestive health care they need to improve their overall health. Trusted by businesses including Texas A&M University, US Foods, and more, Cylinder showcases up to 5:1 ROI and an average of 13% employee engagement. Learn more at cylinderhealth.com.

Synapticure is a virtual clinical care platform dedicated to supporting patients with neurodegenerative diseases, including dementia, Parkinson's, and ALS, throughout the United States. Founded by patients, the company offers comprehensive care services that include access to disease-specific neurologists, speech and language therapy, and 24/7 care coordination. Utilizing advances in science, technology, and computational analytics, Synapticure ensures that patients receive tailored treatment and support in their own homes. The platform integrates medical, dental, vision, and life insurance plans to facilitate easy access to a range of healthcare services, including behavioral health support such as psychiatry and therapy, all aimed at enhancing the quality of life for individuals facing these challenging conditions.

64x Bio develops a platform aimed at accelerating the discovery and optimization of mammalian cell lines for biomanufacturing and therapeutics. The company employs a high-throughput discovery and screening approach combined with an integrated computational design loop to create genetically engineered cell lines tailored for the production of viral vectors. This focus is particularly relevant for cell and gene therapies, as it enhances the efficiency of viral vector production. By providing purpose-built cell lines, 64x Bio enables pharmaceutical and biotechnology companies to improve their manufacturing capacity and reduce costs, ultimately facilitating the timely delivery of innovative therapies to patients.

PostEra is a company focused on advancing drug discovery through innovative technology and strategic partnerships within the biopharma sector. Founded in 2019 and based in Santa Clara, California, PostEra provides medicinal chemistry services that combine molecular design with chemical synthesis. The company has developed algorithms that predict bioactivity and chemical reaction outcomes more effectively than traditional methods, addressing complex challenges in drug development. PostEra collaborates with major pharmaceutical companies and institutions, having secured significant funding and established multi-year partnerships with organizations such as Amgen, Pfizer, and the NIH. Additionally, the company has played a pivotal role in the COVID Moonshot initiative, which is recognized as the largest open-science drug discovery effort to date. By automating the drug development process through its machine learning platform, PostEra aims to enhance the speed, safety, and cost-effectiveness of bringing new drugs to market.

Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.

Mythic Therapeutics is a biotechnology company dedicated to advancing cancer treatment through innovative antibody-drug conjugates (ADCs). The company specializes in a protein engineering approach that enhances the potency of ADCs while maintaining safety, allowing for more effective targeted therapies across various tumor types. By improving the uptake of these therapeutics in cancerous cells and minimizing payload release in healthy cells, Mythic Therapeutics aims to increase the efficacy of treatments without causing significant side effects or toxicity. This technology positions the company to make a meaningful impact in cancer care, enabling healthcare practitioners to better utilize ADCs for a wide array of patients.

Fauna Bio Incorporated is a biotechnology company based in San Francisco, California, founded in 2018. It specializes in developing a cross-mammal drug discovery platform aimed at treating human diseases, including heart disease and neurodegenerative disorders. By studying the mechanisms that allow certain animals, such as hibernating and deep-diving species, to withstand extreme conditions, Fauna Bio seeks to uncover insights that can enhance human health. The company utilizes animal genomics, transcriptomics, metabolomics, and proteomics data from a diverse range of species to identify novel drug targets and facilitate pre-clinical and early clinical testing of new therapeutics. Through its innovative approach, Fauna Bio aims to improve recovery from serious medical events like trauma, heart attacks, and strokes.

Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

Bayesian Health Inc. is a digital health company based in New York, established in 2016. It specializes in an AI-driven platform that enhances patient monitoring by assessing illness severity and detecting changes in acuity. This technology integrates with hospital electronic medical records (EMR), allowing clinical staff and hospital leadership to access real-time data and insights. The platform provides actionable early detection alerts and supports decision-making in complex clinical environments, ultimately optimizing patient care throughout their hospital stay. By leveraging existing investments in EMR systems, Bayesian Health enables healthcare providers to make informed, data-driven decisions that improve safety and efficiency in patient management.

Enveda Biosciences is a biotechnology company focused on drug discovery through the exploration of chemical diversity found in nature. Utilizing AI-powered tools, the company develops a robust database of chemical molecules derived from living organisms. Enveda's platform integrates machine learning, metabolomics, and robotics to analyze natural samples for their chemical structures and biological activities. This innovative approach allows for the efficient identification of potential new medicines, including antibiotics and hypotensives, without the need for isolating individual compounds or conducting extensive experiments. By harnessing nature's hidden chemistry, Enveda aims to accelerate the development of novel therapeutics for the healthcare industry.

Sempre Health, Inc. operates a behavior-based healthcare pricing platform that collaborates with health plans and pharmaceutical manufacturers to offer dynamic co-payment adjustments based on individual patient adherence and behavior. Founded in 2015 and based in San Francisco, the company analyzes prescription records to forecast the most appropriate price for medications based on a patient's timely adherence. Patients receive personalized SMS messages that inform them of potential discounts and encourage prompt prescription refills, such as alerts indicating that filling a prescription today may cost $10, while delaying could raise the price to $30. This innovative approach not only aims to improve patients' access to affordable care but also generates valuable real-world data on patient price sensitivities and cost behaviors.

Wren Therapeutics Limited is a biopharmaceutical company based in Cambridge, United Kingdom, that specializes in the development of small molecule therapeutics targeting protein misfolding diseases. Founded in 2016, the company focuses on conditions such as Alzheimer's and Parkinson's diseases, type 2 diabetes, and various rare forms of amyloidosis. Wren's proprietary technology platform is grounded in a deep understanding of the origins of these diseases, drawing on extensive scientific research conducted at the University of Cambridge and Lund University. Through this innovative platform, Wren aims to advance drug discovery and development for a range of serious neurological and rare disorders.

Sitka, Inc. operates an online communication platform that connects patients with healthcare providers across various specialties, including endocrinology, neurology, orthopedics, pulmonology, and rheumatology. Founded in 2018 by experts in healthcare, technology, and policy, the company aims to transform specialty care in the United States by enhancing the capabilities of primary care providers and facilitating patient involvement in their care. The platform allows for personalized consultations, such as interpreting MRI results with board-certified doctors, thereby improving patients' understanding of their health conditions and enabling better decision-making. Headquartered in Carmel, California, Sitka is supported by a range of investors and is dedicated to fostering effective and trusted care delivery for all patients through its innovative solutions.

People Science is a technology-driven research and development platform focused on alternative medicine. The company facilitates connections between health-conscious individuals, medical professionals, and research scientists while supporting manufacturers in creating products grounded in scientific testing. By providing a scaled research platform, People Science enables customers to identify alternative medicines that may aid in their wellness journeys, ensuring that these solutions are backed by rigorous research and evidence.

Transition Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, with an additional office in Cambridge, United Kingdom. Founded in 2020, the company specializes in the discovery, analysis, and modulation of biological condensates. It has developed a unique platform, known as Condensomics, which facilitates hypothesis-free drug discovery and diagnostics. Transition Bio utilizes advanced droplet microfluidic techniques and protein biophysics to characterize condensates with high precision, thereby creating extensive opportunities for drug development. The company's innovative approach aims to advance human health care by providing detailed insights into molecular structures.

Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.

Sonoma Biotherapeutics develops adoptive Treg cell therapies aimed at treating autoimmune and degenerative diseases. The company employs advanced genome editing and target-specific cell therapy to create therapeutic solutions that promote self-tolerance and mitigate harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded in 2019 and headquartered in South San Francisco, California, with an additional office in Seattle, Washington, Sonoma Biotherapeutics combines expertise in Treg biology and proprietary methodologies to advance its therapeutic platform, focusing on developing disease-modifying and potentially curative treatments.

Sonoma Pharmaceuticals, Inc. is a global healthcare company that develops and produces stabilized hypochlorous acid (HOCl) products for diverse applications, including wound care, dermatology, animal health, eye care, and oral care. Based in Woodstock, Georgia, and incorporated in 1999, the company offers over 100 commercially available products worldwide. Its key offerings include Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription product for managing dermatoses; Celacyn gel for scar management; and SebuDerm for seborrhea relief. Additionally, Sonoma provides Acuicyn for eye care, Microcyn for expedited wound healing, and various products targeting animal health, such as MicrocynAH and MicrocynVS. The company's focus on addressing unmet medical needs in chronic skin conditions significantly contributes to enhancing patient care while aiming to reduce overall healthcare costs. Sonoma Pharmaceuticals was previously known as Oculus Innovative Sciences, Inc. and rebranded in December 2016.

TARA Biosystems, Inc. is a biotechnology company focused on developing organ-on-a-chip technology, specifically human cardiac tissue models, to enhance drug discovery and safety assessments. Founded in 2014 and based in the United States, the company utilizes stem cell-derived cardiac tissue that mimics adult physiological conditions, enabling precise measurement of cardiac functionality. This innovative platform aims to facilitate the faster and safer development of new therapies by providing predictive in vitro models that can assess the effects of drug compounds on heart function without the need for human testing. Through its advanced technology, TARA Biosystems seeks to improve the health of patients by enabling more reliable assessments of cardiac drug efficacy and safety.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.

Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.

Notable Labs, Inc. is a clinical-stage company that specializes in personalized lab testing services for cancer patients, particularly those with brain cancer. Founded in 2014 and based in Foster City, California, the company utilizes its proprietary Predictive Precision Medicines Platform to conduct drug combination experiments on patients' tumors. This platform allows Notable Labs to simulate cancer treatments and predict patient responses to specific therapies, enabling healthcare providers to prioritize combinations of FDA-approved treatments that can be prescribed without the need for clinical trials. By providing detailed reports to physicians, Notable Labs aims to enhance treatment efficacy and expedite therapeutic development for patients.

Wren Therapeutics Limited is a biopharmaceutical company based in Cambridge, United Kingdom, that specializes in the development of small molecule therapeutics targeting protein misfolding diseases. Founded in 2016, the company focuses on conditions such as Alzheimer's and Parkinson's diseases, type 2 diabetes, and various rare forms of amyloidosis. Wren's proprietary technology platform is grounded in a deep understanding of the origins of these diseases, drawing on extensive scientific research conducted at the University of Cambridge and Lund University. Through this innovative platform, Wren aims to advance drug discovery and development for a range of serious neurological and rare disorders.

Cricket Health Inc. is a specialty kidney care provider focused on delivering integrated nephrology and dialysis services for individuals with Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD). Founded in 2015 and based in San Francisco, California, the company employs a technology-enabled, evidence-based approach to manage kidney diseases. Cricket Health aims to enhance patient outcomes and value for healthcare partners by providing multidisciplinary care both in-person and virtually. Their services are designed to keep patients healthy, reduce hospitalizations, accelerate access to transplants, and promote home dialysis adoption. By identifying at-risk patients and acting early, Cricket Health supports personalized treatment options that include transplant support, home dialysis, conservative care, and in-center dialysis.

Sempre Health, Inc. operates a behavior-based healthcare pricing platform that collaborates with health plans and pharmaceutical manufacturers to offer dynamic co-payment adjustments based on individual patient adherence and behavior. Founded in 2015 and based in San Francisco, the company analyzes prescription records to forecast the most appropriate price for medications based on a patient's timely adherence. Patients receive personalized SMS messages that inform them of potential discounts and encourage prompt prescription refills, such as alerts indicating that filling a prescription today may cost $10, while delaying could raise the price to $30. This innovative approach not only aims to improve patients' access to affordable care but also generates valuable real-world data on patient price sensitivities and cost behaviors.

Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.

Sitka, Inc. operates an online communication platform that connects patients with healthcare providers across various specialties, including endocrinology, neurology, orthopedics, pulmonology, and rheumatology. Founded in 2018 by experts in healthcare, technology, and policy, the company aims to transform specialty care in the United States by enhancing the capabilities of primary care providers and facilitating patient involvement in their care. The platform allows for personalized consultations, such as interpreting MRI results with board-certified doctors, thereby improving patients' understanding of their health conditions and enabling better decision-making. Headquartered in Carmel, California, Sitka is supported by a range of investors and is dedicated to fostering effective and trusted care delivery for all patients through its innovative solutions.

Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.

Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

Floreo Inc., founded in 2016 and based in Washington D.C., develops a virtual reality learning app designed to teach social and communication skills to individuals with autism spectrum disorder, as well as those with ADHD and anxiety. The platform allows supervising adults to monitor and guide activities, making it a valuable tool for therapy clinics and school districts. Floreo is used by over 100 therapy clinic businesses and school districts, and has partnered with Meta to expand its reach in public schools.

Notable Labs, Inc. is a clinical-stage company that specializes in personalized lab testing services for cancer patients, particularly those with brain cancer. Founded in 2014 and based in Foster City, California, the company utilizes its proprietary Predictive Precision Medicines Platform to conduct drug combination experiments on patients' tumors. This platform allows Notable Labs to simulate cancer treatments and predict patient responses to specific therapies, enabling healthcare providers to prioritize combinations of FDA-approved treatments that can be prescribed without the need for clinical trials. By providing detailed reports to physicians, Notable Labs aims to enhance treatment efficacy and expedite therapeutic development for patients.

Vineti, Inc. is a technology company that specializes in developing solutions for the therapeutic delivery of personalized medicine, particularly focusing on cell and gene therapies. Founded in 2016 and headquartered in San Francisco, California, with additional offices in Bethesda, Maryland, and Yerevan, Armenia, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform streamlines and automates patient-centric supply chains, facilitating the efficient management of operations, manufacturing, quality control, and regulatory compliance for advanced therapies, including CAR-T cell therapies for late-stage cancer. Vineti's solutions aim to enhance patient access to life-saving treatments while addressing the challenges faced by patients, healthcare providers, pharmaceutical companies, and regulators in the commercialization of personalized medicine. By providing tools for supply chain orchestration and maintaining an audit trail for the handling of cell products, Vineti positions itself as a critical player in the evolving landscape of personalized therapeutics.

Clover Health Inc. is a health insurance company that specializes in providing Medicare Advantage plans primarily for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company operates in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health utilizes a Preferred Provider Organization (PPO) platform to enhance the quality of life for its members and their healthcare providers. The company employs patient-centered analytics and a dedicated care management team to identify potential health risks and deliver preventive care, thereby aiming to minimize avoidable spending and manage chronic diseases. Its proprietary software platform, Clover Assistant, offers personalized insights to physicians, supporting early detection and effective management of chronic conditions. Clover Health generates the majority of its revenue from its insurance segment, which includes both PPO and HMO plans.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.

Circle Pharma, Inc. is an early-stage biotechnology company based in South San Francisco, California, founded in 2012 by Matt Jacobson and Scott Lokey. The company focuses on developing cell-permeable macrocyclic peptide therapeutics by employing proprietary computational design algorithms and innovative synthetic chemistry. Circle Pharma utilizes an iterative design process that leverages large virtual libraries of conformationally diverse macrocycle scaffolds, which are selected for their inherent permeability. This approach allows the company to create first-in-class macrocycle therapies that can be administered through multiple routes, including oral delivery. The therapeutics target challenging clinical issues, particularly intracellular protein-protein interactions that are significant contributors to cancer, thereby addressing unmet medical needs and enhancing the capabilities of healthcare professionals in their treatment efforts.

Advantia Health, LLC is a healthcare delivery company based in Arlington, Virginia, founded in 2014. It specializes in providing comprehensive services in obstetrics and gynecology, primary care, and mental wellness, primarily focused on women's health and that of their families. The company operates additional locations in Virginia, Maryland, Illinois, and Missouri. Advantia Health utilizes technology to deliver high-quality, efficient care through outpatient facilities and offers telehealth services, enabling patients to connect with healthcare providers via web and mobile applications. This approach ensures that patients receive timely and appropriate medical guidance tailored to their needs.

Dr.Consulta is a Brazilian healthcare company that operates a network of clinics designed to provide quality medical care at affordable prices. Initially established as a full-service primary care provider, the company has since evolved into a Health Maintenance Organization (HMO) targeting uninsured individuals. Dr.Consulta offers a variety of outpatient services, including scheduled appointments, consultations, and examinations for general medical issues such as gynecology and pediatrics. By facilitating access to healthcare professionals, the company aims to deliver essential medical services to a wider population, ensuring that individuals can receive the care they need without financial strain.

Verge Genomics is a biotechnology company focused on transforming drug discovery for neurodegenerative diseases through the application of artificial intelligence. Founded by experts in machine learning and seasoned drug developers in neuroscience, the company aims to leverage advances in computational genomics and insights into brain science to identify promising therapeutic targets. Its drug discovery platform utilizes machine learning algorithms to analyze large datasets, enabling the identification of effective drugs and accelerating the development of life-saving treatments. By improving the efficiency of the drug development process, Verge Genomics seeks to enhance patient outcomes and reduce the overall costs associated with pharmaceutical development.

Included Health is a healthcare company that provides a blend of virtual care, navigation, and community-based healthcare services to enhance the member experience. It combines advanced technology and a compassionate approach to deliver personalized care guidance and advocacy, ensuring that individuals receive the right care at the right time. The company's offerings include access to both virtual and in-person services for a range of healthcare needs, including urgent and primary care, behavioral health, and specialty care. By focusing on a member-centric model, Included Health aims to raise the standard of healthcare for everyone, making it simpler and more effective for individuals to navigate their health journey.

Aspire Health, Inc. is a healthcare company based in Nashville, Tennessee, that operates a network of outpatient palliative care practices for patients with serious illnesses. Established in 2012, the company focuses on providing relief from symptoms, pain, and stress associated with conditions such as cancer, congestive heart failure, chronic obstructive pulmonary disease, kidney failure, liver failure, advanced dementia, and amyotrophic lateral sclerosis. Aspire Health supports patients and their caregivers by navigating the healthcare system, aiding in complex treatment decisions, and offering emotional and spiritual guidance. The organization delivers home-based and outpatient clinical services across several Middle Tennessee counties, including Davidson, Robertson, Rutherford, Sumner, Williamson, and Wilson. Aspire Health operates as a subsidiary of Nash Holding Company and emphasizes disease management and care coordination across various settings, including outpatient clinics and assisted living centers.

One Medical is a membership-based healthcare platform that offers a range of concierge medical services, combining digital health solutions with in-person care. Founded in 2007 and headquartered in San Francisco, California, the company aims to enhance the patient experience by providing seamless access to healthcare, including virtual video visits available at any time. By focusing on building personal relationships between healthcare providers and patients, One Medical seeks to improve health outcomes while reducing costs. The organization is committed to challenging the traditional healthcare model through its technology-powered, human-centered approach, ensuring that members receive high-quality care that is convenient and effective.

HeartFlow, Inc. is a medical technology company that specializes in non-invasive solutions for coronary artery disease detection. Founded in 2007 and based in Redwood City, California, with additional offices in Portland, Austin, London, and Tokyo, the company offers its HeartFlow Analysis, which utilizes data from standard computerized tomography scans to create personalized three-dimensional models of a patient's heart. This analysis helps clinicians evaluate the impact of blockages on blood flow, facilitating informed treatment decisions while minimizing the need for invasive testing. HeartFlow's technology integrates over two decades of scientific research with advancements in artificial intelligence, making its HeartFlow FFRCT Analysis available in the United States, Canada, Europe, the United Kingdom, and Japan.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.